Figure 5 | Blood Cancer Journal

Figure 5

From: 18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib

Figure 5

Increasing abundance of aberrant plasma cells in the course of IL6Myc-driven tumor formation. (a) Mean histopathology scores of tissue infiltration with abnormal PCs at early (top), mid (center) and late (bottom) stages of PCT development as defined in the top panel. The scoring system distinguishes lack of such PCs (0), presence of <50% (1) or <80% (2) of PCs, >80% (3), and complete effacement of normal histology by PCT (4). (b) Representative hematoxylin and eosin (H&E)-stained tissue sections of secondary lymphoid tissues (lymph nodes, left) and nonlymphoid tissues (liver sections, right) at early (top), mid (center) and late (bottom) stages of PCT development. In the lymph node images, aggregates of normal lymphocytes are circled in blue to facilitate comparison with aberrant PCs. Plasmacytic infiltrates in liver (that is, portal pattern in the mid-stage example and interstitial pattern in the late-stage example) are circled in red.

Back to article page